In a nutshell This study wanted to assess the safety and effectiveness of inotuzumab ozogamicin (InO; Besponsa) for the treatment of children with unresponsive acute lymphoblastic leukemia (ALL). Researchers found that InO was safe and effective in this group of patients. Some background Acute lymphoblastic leukemia (ALL) is a cancer of the bone...
Read MoreCurrent treatment status-Undergoing active treatment-Partial response Posts on Medivizor
Evaluating long-term outcomes of ibrutinib for relapsed or refractory mantle cell lymphoma
In a nutshell This study evaluated the long-term outcomes of ibrutinib (Imbruvica) treatment in patients with relapsed or refractory (does not respond to treatment) mantle cell lymphoma (MCL). This study concluded that ibrutinib is effective and well-tolerated in these patients. Some background MCL is a rare but aggressive type of non-Hodgkin’s...
Read MoreSearching for patients with relapsed or refractory Hodgkin’s lymphoma to try pembrolizumab plus GVD
In a nutshell This trial is evaluating the effects of second-line pembrolizumab (Keytruda) plus GVD (gemcitabine, vinorelbine, doxorubicin) for relapsed (recurrent cancer) or refractory (does not respond to treatment) Hodgkin’s lymphoma (HL). The main outcome to be measured is the number of patients who achieve a complete response...
Read MoreIs Daratumumab added to bortezomib plus dexamethasone better in treating multiple myeloma?
In a nutshell This article investigated the safety and effectiveness of adding daratumumab (Darzalex) to bortezomib (Velcade) and dexamethasone (Decadron) for the treatment of relapsed or refractory (does not respond to treatment) multiple myeloma (RRMM). The authors concluded that the addition of daratumumab is safe and gave the greatest benefit to...
Read MoreEvaluating brentuximab vedotin after alloSCT in patients with recurrent Hodgkin Lymphoma
In a nutshell This study evaluated the outcomes of brentuximab vedotin (Adcetris) treatment for patients with relapsed (recurrent) or progressive (tumor grows or spreads) Hodgkin’s lymphoma (HL) after allogeneic (allo) stem cell transplantation (SCT). This study concluded that brentuximab vedotin is safe and effective for these patients. Some...
Read MoreEvaluating the long-term outcomes of brentuximab vedotin after stem cell transplantation for classical Hodgkin’s lymphoma
In a nutshell This study evaluated the long-term survival and safety of brentuximab vedotin (Adcetris) treatment for patients with classical Hodgkin’s lymphoma (cHL) after autologous stem cell transplantation (auto-SCT; patient's own healthy stem cells are retrieved and then returned into the body after cancer has been removed with chemotherapy...
Read MoreEvaluating lenalidomide plus everolimus for relapsed or refractory lymphoma
In a nutshell This study investigated the effectiveness and safety of lenalidomide (Revlimid) plus everolimus (Afinitor) in pretreated patients with relapsed (recurrent) or refractory (does not respond to treatment) lymphoma. This study concluded that this combination was well-tolerated and showed promising effectiveness in these patients. Some...
Read MoreThe safety of elotuzumab, lenalidomide and dexamethasone in unresponsive multiple myeloma.
In a nutshell This paper compared the safety and effectiveness of elotuzumab (Empliciti) plus lenalidomide (Revlimid) and dexamethasone (Decadron) with lenalidomide and dexamethasone in unresponsive multiple myeloma. It was found that elotuzumab plus lenalidomide and dexamethasone was more effective than lenalidomide and dexamethasone alone. Some...
Read MoreEvaluating radioimmunotherapy versus rituximab maintenance therapy in follicular lymphoma
In a nutshell This study compared the outcomes of radioimmunotherapy versus rituximab (Rituxan) maintenance therapy in patients with follicular lymphoma (FL). This study concluded that radioimmunotherapy shows similar survival outcomes compared to rituximab maintenance therapy in patients with FL. Some background In patients with FL, rituximab...
Read MoreEvaluating BendaEAM chemotherapy before stem cell transplantation for relapsed lymphoma
In a nutshell This study evaluated the effectiveness and safety of the BendaEAM (bendamustine, etoposide, cytarabine, melphalan) in patients with lymphoma undergoing autologous stem cell transplantation (auto-SCT). This study concluded that BendaEAM is a feasible option for these patients, with minimal side effects. Some background High-dose...
Read MoreEvaluating BendaEAM chemotherapy before stem cell transplantation for relapsed lymphoma
In a nutshell This study evaluated the effectiveness and safety of the BendaEAM (bendamustine, etoposide, cytarabine, melphalan) in patients with lymphoma undergoing autologous stem cell transplantation (auto-SCT). This study concluded that BendaEAM is a feasible option for these patients, with minimal side effects. Some background High-dose...
Read MoreEvaluating venetoclax monotherapy for relapsed or refractory mantle cell lymphoma
In a nutshell This study evaluated the effectiveness and safety of venetoclax (Venclexta) monotherapy (single-agent treatment) in patients with relapsed (cancer recurrence) or refractory (does not respond to initial treatment) mantle cell lymphoma (MCL). This study concluded that venetoclax monotherapy is promising, with minimal side effects. Some...
Read More
